• Adrian Simpson, United States says, "If you are looking for a fair deal on medical supplies, IDM is something I would seriously recommend. Am hooked for life."
  • Craig, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "IDM makes online shopping a pleasure. Shopping is so simple that you just breeze through it."
  • Harry Mason, United States says, "I have to admit am a bit of a lazy bloke when it comes to ordering online .And IDM pampers me to the hit as it's so simple to order."
  • John Hanks, United States says, "I was a sceptic until my first order. After, I received my first package, I turned believer. Now, it’s been 3 years since I have been ordering from IDM."
  • Natalie Wallace, United States says, "I was apprehensive about how my doubts would be addressed but what the heck,I went ahead and placed my order. Customer service was patient and helped me out."
  • Mark Penning, United States says, "Happy I got my package just in time for my vacation. Needless to say, it made my holiday a wonderfully satisfying experience."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    You can find the latest happening of our pharmacy
    Follow us on Twitter

      Pharma firms rush for in-licensing deals

      Posted AtBusiness-Standard

      Domestic pharma companies are rushing to clinch in-licensing deals with global players with a view to stemming loss of business and warding off any patent-related troubles.

      Except for multinational pharmaceutical players and a few local giants like Ranbaxy, most medium-to-large pharma companies have entered into licensing agreements with foreign counterparts. The companies that have entered into such deals include JB Chemicals, Lupin and Nicholas Piramal.

      An in-licensing deal allows a domestic pharma player to manufacture and sell products of a foreign company in India officially without any kind of patent infringement.

      It is a win-win situation for both the parties: the domestic company gets the technological knowhow and the foreign ally can get a toe-hold in the complex Indian market.

      This model enables the domestic company to introduce a molecule or a formulation with the right technology in India and the foreign player to get a credible local partner. With duplication and infringement becoming next to impossible, this gives a vast market to the partners.

      Panacea Biotec has in-licensed a peptide-based technology for alopecia management from the National Institute of Health of the US.

      The patent-protected technology for actin-binding peptide/ poly peptide stimulates hair growth and regenerates lost hair follicles.

      Ranbaxy Laboratories has signed such a pact with J B Chemicals to market the herbal range brand, Doktor Mom, in the Romanian market.

      Nicholas Piramal has struck deals with global players such as Boehringer Mannheim, Allergan, Boots, Chiesi Farmaceutici, Biogen Idec, Genzyme, Ethypharm and Laboratories, Pierre Fabre, besides working closely with Aventis and Novartis.

      Elder Pharmaceuticals has partnered in-licensing with 25 international companies.

      Some of the in-licensing partners of Elder include Haw Par Healthcare (Singapore) for Tiger Balm, Blistex Inc (USA) for lip care products, Zambon SpA of Italy for Fluimicil (anti-ashthma), TRB Chemedica of Switzerland for Artrodar (anti-arthritis), Covex (Spain) for Citicholine (cerebro neuropsychiatry segment) and Ferrer (Spain) for Vimpocetine (cerebro neuropsychiatry segment).

      January 12, 2006


      Share this Article!

    Back to top^